VITRO BIOPHARMA, INC. — Operating Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/08465b74-df10-4880-8960-d2006dbbc8c3/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-5.0M | 2024-11-01 – 2025-10-31 | evidence 0001493152-26-006592 |
| FY 2024 | $-9.2M | 2023-11-01 – 2024-10-31 | evidence 0001493152-25-003942 |
| FY 2023 | $-5.4M | 2022-11-01 – 2023-10-31 | evidence 0001493152-24-004126 |
| FY 2022 | $-6.0M | 2021-11-01 – 2022-10-31 | evidence 0001493152-24-004126 |
| FY 2015 | $-158.1k | 2014-11-01 – 2015-10-31 | evidence 0001376474-16-000845 |
| FY 2014 | $-171.0k | 2013-11-01 – 2014-10-31 | evidence 0001011034-15-000022 |
| FY 2013 | $-24.9k | 2012-11-01 – 2013-10-31 | evidence 0001294606-14-000052 |
| FY 2012 | $-179.1k | 2011-11-01 – 2012-10-31 | evidence 0001294606-14-000020 |
| FY 2011 | $-202.5k | 2010-11-01 – 2011-10-31 | evidence 0001376474-12-000037 |
| FY 2010 | $-261.2k | 2009-11-01 – 2010-10-31 | evidence 0001376474-12-000037 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).